SARS-CoV-2, the virus that causes COVID-19, has taken the world by surprise, just as HIV did in the 1980’s. However, unlike HIV, the world has come together and shown that a coordinated, global response to a pandemic is possible in record time. Many aspects of this response, including the search for a vaccine, have built upon technologies and lessons learned from recent epidemics, including HIV.
Every year, World Immunization Week is celebrated during the last week of April with the aim of promoting the use of vaccines to protect people against infectious diseases. Although much progress has been made to develop vaccines, an HIV vaccine remains elusive. In this post we revisit one of the most promising HIV prevention vaccine studies that was prematurely halted due to lack of efficacy and highlight its critical role in informing HIV vaccine development.
The Enterprise is relaunching the “Bench to Clinic” web tool in the context of ongoing efficacy trials, a rich pipeline of new products and new approaches to the design and development of HIV vaccines. The tools provides an overview of the necessary steps in the process and estimates of corresponding timelines and budgets. It also drew attention to some potential challenges and provided links to relevant resources.